# 此交易大幅強化 Sun 的全球商業能力，擁有超過 24,000 人的前端團隊，並遍及多個大型市場。

*business · news · 2026-04-29 · Business Standard*

## Key points

- Sun Pharma 的收購使其營收組合轉向新興市場，並減少對印度和美國的依賴。
- 此交易讓 Sun 獲得 Organon 8 億美元的中國業務，將中國定位為主要成長動力。
- Organon 的商業前端使 Sun 能在全球推出自有創新及授權產品。
- Organon 缺乏內部 API 製造能力，為 Sun 的整合供應鏈帶來成本優化機會。
- 印度製造產能擴充最終可能包含 Organon 產品，但須待法規核准後才會實施。

At the core of the strategy is the ability to use this established front-end—something that would have taken years to build organically—to expand in underpenetrated regions while creating a ready platform to launch innovative and in-licensed products. The deal significantly strengthens Sun’s global commercial capabilities, with a 24,000-plus front-end team and presence across multiple large markets, enhancing its ability to emerge as a partner of choice for global in-licensing opportunities, according to Elara Securities. Post-acquisition, Sun’s geographic mix shifts meaningfully towards a more balanced global profile. Currently, it derives about 33 per cent of revenue from India and 31 per cent from the US, with 18 per cent from emerging markets and 14 per cent from the rest of the world. In the combined entity, India’s share drops to 17 per cent and the US to 27 per cent, while emerging markets rise to 29 per cent and the rest of the world plus others to 28 per cent, reflecting reduced dependence on any single geography. Elara Securities described the transaction as a “step-change” in Sun’s long-term strategy, accelerating its transition towards a globally diversified, innovation-driven pharmaceutical company with multiple growth engines across specialty, branded generics, and biosimilars. China is central to this thesis. Describing it as a “very exciting story,” Kirti Ganorkar, MD, Sun Pharma, pointed to the country’s $150 billion pharmaceutical market growing at 5 to 7 per cent, where Organon already has a sizeable $800 million business anchored in established brands. Despite intense generic competition, these brands retain strong equity among physicians and patients, providing a base for growth. Sun plans to build on this through lifecycle management—adding new formulations and line extensions—while also tapping into China’s innovation ecosystem. With no manufacturing footprint in China, the immediate opportunity lies in using the front-end to scale existing products and introduce new therapies, including innovative medicines. Japan, however, presents a more structurally constrained opportunity. While Organon offers a commercial foothold, the established products segment faces annual price erosion of 5 to 7 per cent under the reimbursement system. As a result, Sun’s strategy is to focus on innovation-led expansion while treating the established brands business as stable to gradually declining. “The established product business doesn’t really grow in Japan... innovation is what you can focus on,” Ganorkar said. The commercial leverage also extends to Ilumya and Sun’s broader specialty portfolio, where Organon’s front-end provides a ready platform for expansion. “Right now, we market through our partners... but all our future innovative products, then we will have an ability to launch through this commercial front end,” Ganorkar said. Analysts expect this platform to play a central role in scaling innovative therapies, with HDFC Securities noting that in-licensing will be a key pillar of the combined entity’s strategy, particularly for expanding its innovative medicines portfolio across emerging markets. Beyond innovation, the company is expected to accelerate growth in Organon’s branded generics portfolio, especially in therapies such as cardiology, dermatology, bone health, and ophthalmology, while also scaling established brands in India, according to HDFC Securities. The brokerage added that Organon’s commercial platform could strengthen Sun’s ability to pursue future in-licensing opportunities, including biosimilars. A key structural difference lies in manufacturing and API sourcing. Organon does not have in-house API manufacturing and relies on external suppliers, including legacy MSD-linked ecosystems. Sun, in contrast, has deep backward integration with significant in-house API capabilities and a diversified supplier base. This creates a medium-term opportunity for cost optimisation and supply chain consolidation, although any transition will be gradual. Sun is also expanding its manufacturing footprint through new greenfield facilities in India. While it may eventually manufacture select Organon products in India, management indicated this would be a multi-year process dependent on regulatory approvals and supply chain requalification.

**Companies:** Sun Pharma, Organon
**Countries:** India, United States, China, Japan

[Read the full story on Business Standard](https://www.business-standard.com/companies/news/sun-pharma-organon-acquisition-global-expansion-in-licensing-strategy-126042901068_1.html)

---

Canonical: https://newsio.io/zh-TW/n/6eea0b11-becb-4f21-aa26-151b2fcd63af/sun-24000-sun
Summarized by Newsio from Business Standard. https://newsio.io/how-it-works